More evidence suggests a disproportionately greater risk of bladder cancer from Takeda Pharmaceuticals’ Actos than with other oral diabetic medications.Litigation from affected diabetics is to be expected, although a direct link between Actos use and bladder cancer hasn’t been definitively established. Consequently, the company has little to fear monetarily. Management does, however, need to worry about another ticking clock: Aug. 17, 2012, is when Watson Pharmaceuticals (WPI), Mylan (MYL) and Ranbaxy Labs (RBXLF) will launch the first wave of generic competitors to branded Actos in the U.S.
Read More: CBS Interactive ....
Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.
No comments:
Post a Comment